Delmitide

Drug Profile

Delmitide

Alternative Names: Allotrap 1258; Rationally Designed Peptide 58; RDP 1258; RDP 58

Latest Information Update: 20 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genzyme Corporation
  • Developer Synt:em
  • Class Anti-inflammatories; Peptides
  • Mechanism of Action Cytokine inhibitors; Immunosuppressants; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Crohn's disease; Ulcerative colitis
  • Discontinued Atopic dermatitis; Barrett's oesophagus; Chemotherapy-induced damage; Diarrhoea; Heart transplant rejection; HIV infections; Interstitial cystitis; Multiple sclerosis; Psoriasis; Pulmonary fibrosis; Respiratory tract disorders; Uveitis

Most Recent Events

  • 26 May 2010 No development reported - Phase-I for Crohn's disease in USA (PO)
  • 26 May 2010 No development reported - Phase-I for Ulcerative colitis in USA (PO)
  • 26 May 2010 No development reported - Phase-II for Crohn's disease in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top